Collaborative Services Agreement

ValiRx PLC

26 April 2023

 

ValiRx PLC

("ValiRx" or the "Company")

Collaborative Services Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that the Company's wholly owned subsidiary, Inaphaea BioLabs Limited ("Inaphaea"), has entered into a collaborative services agreement with Physiomics plc (AIM:PYC) ("Physiomics") ("Collaborative Services Agreement").

The Collaborative Services Agreement recognises the synergy between Inaphaea's growing capabilities as a translational contract research organisation (tCRO®) and Physiomics' capabilities for advanced statistical analyses, machine learning techniques, data handling and visualisation, as well as biological modelling.

Under the agreement, service users of Inaphaea will be able to benefit from Physiomics capabilities in a single service contract with Inaphaea.  Designed to offer a seamless integration of data generation and data interpretation, this collaborative method of working provides benefits to both companies as well as to the service users.

Dr Suzy Dilly, CEO at ValiRx explains "The Collaborative Services Agreement is the first step towards converting Inaphaea into a full service tCRO®.  The Physiomics modelling skills will enable our clients to interpret and build on the data generated within the Inaphaea facility.  I am delighted to be able to offer this additional service module to our clients.  This additional value-added service will be available to our first service users, with benefits expected to increase as more complex data generation technologies are added to our capabilities."

Dr Jim Millen, CEO at Physiomics commented "The Collaborative Services Agreement will expand the scope of our core consulting business to discovery stage projects and improve our access to clients focused on earlier stages of drug development, while at the same time supporting Inaphaea's own service offering.  The synergy is clear and both the scientific and commercial ambitions of our two companies are well matched.  We look forward to working closely with ValiRx through this initiative."

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO Inaphaea BioLabs Limited Dr Andrew Carnegie, Head of Strategic Commercial Development	Tel: [phone] www.valirx.com [e-mail] www.inaphaea.com [e-mail]
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	[phone] www.vformation.biz [e-mail] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	Tel: [phone]
Cenkos Securities plc (Joint Broker) Russell Kerr/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance)	Tel: [phone]
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker	Tel: [phone]

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Their approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and their proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 40 targets and 70 drugs.  Physiomics' clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

END